<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39349767</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-7254</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Acta pharmacologica Sinica</Title><ISOAbbreviation>Acta Pharmacol Sin</ISOAbbreviation></Journal><ArticleTitle>Tofacitinib prevents depressive-like behaviors through decreased hippocampal microgliosis and increased BDNF levels in both LPS-induced and CSDS-induced mice.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41401-024-01384-8</ELocationID><Abstract><AbstractText>Depressive disorders are a global mental health challenge that is closely linked to inflammation, especially in the post-COVID-19 era. The JAK-STAT pathway, which is primarily associated with inflammatory responses, is not fully characterized in the context of depressive disorders. Recently, a phase 3 retrospective cohort analysis heightened that the marketed JAK inhibitor tofacitinib is beyond immune diseases and has potential for preventing mood disorders. Inspired by these clinical facts, we investigated the role of the JAK-STAT signaling pathway in depression and comprehensively assessed the antidepressant effect of tofacitinib. We found that aberrant activation of the JAK-STAT pathway is highly conserved in the hippocampus of classical depressive mouse models: LPS-induced and chronic social defeat stress (CSDS)-induced depressive mice. Mechanistically, the JAK-STAT pathway mediates proinflammatory cytokine production and microgliosis, leading to synaptic defects in the hippocampus of both depressive models. Remarkably, the JAK inhibitor tofacitinib effectively reverses these phenomena, contributing to its antidepressant effect. These findings indicate that the JAK/STAT pathway could be implicated in depressive disorders, and suggest that the JAK inhibitor tofacitinib has a potential translational implication for preventing mood disorders far beyond its current indications.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gao</LastName><ForeName>Ya-Nan</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, 210009, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pan</LastName><ForeName>Kai-Jun</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, 210009, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong-Mei</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Ying-Bei</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wen-Gang</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, 210009, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zong</LastName><ForeName>Hai-Chao</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Hao-Ran</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jin-Wen</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xing-Chen</ForeName><Initials>XC</Initials><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Zi-Tong</ForeName><Initials>ZT</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, 210009, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ze</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, 210009, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Lingang Laboratory, Shanghai, 200120, China. yzang@lglab.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, 210009, China. jli@simm.ac.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. jli@simm.ac.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China. jli@simm.ac.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, China. jli@simm.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Pharmacol Sin</MedlineTA><NlmUniqueID>100956087</NlmUniqueID><ISSNLinking>1671-4083</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">JAK-STAT pathway</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">microgliosis</Keyword><Keyword MajorTopicYN="N">synaptic defects</Keyword><Keyword MajorTopicYN="N">tofacitinib</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349767</ArticleId><ArticleId IdType="doi">10.1038/s41401-024-01384-8</ArticleId><ArticleId IdType="pii">10.1038/s41401-024-01384-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299–312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31948-2</ArticleId><ArticleId IdType="pubmed">30396512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157:1552–62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.157.10.1552</ArticleId><ArticleId IdType="pubmed">11007705</ArticleId></ArticleIdList></Reference><Reference><Citation>Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065 https://doi.org/10.1038/nrdp.2016.65</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.65</ArticleId><ArticleId IdType="pubmed">27629598</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunier A. COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide. WHO website (2022). https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide .</Citation></Reference><Reference><Citation>Fang M, Li Y, Liao Z, Wang G, Cao Q, Li Y, et al. Lipopolysaccharide-binding protein expression is increased by stress and inhibits monoamine synthesis to promote depressive symptoms. Immunity. 2023;56:620–34.e611. https://doi.org/10.1016/j.immuni.2023.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2023.02.002</ArticleId><ArticleId IdType="pubmed">36854305</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyre HA, Air T, Pradhan A, Johnston J, Lavretsky H, Stuart MJ, et al. A meta-analysis of chemokines in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;68:1–8. https://doi.org/10.1016/j.pnpbp.2016.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2016.02.006</ArticleId><ArticleId IdType="pubmed">26903140</ArticleId><ArticleId IdType="pmc">5536843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CH, Giuliani F. The role of inflammation in depression and fatigue. Front Immunol. 2019;10:1696.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01696</ArticleId><ArticleId IdType="pubmed">31379879</ArticleId><ArticleId IdType="pmc">6658985</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez-Sánchez G, Becerril-Villanueva E, Arreola R, Martínez-Levy G, Hernández-Gutiérrez ME, Velasco-Velásquez MA, et al. Inflammatory profiles in depressed adolescents treated with fluoxetine: an 8-week follow-up open study. Mediators Inflamm. 2018; 4074051. https://doi.org/10.1155/2018/4074051 .</Citation></Reference><Reference><Citation>Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;8:94 https://doi.org/10.1186/1742-2094-8-94</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-94</ArticleId><ArticleId IdType="pubmed">21831269</ArticleId><ArticleId IdType="pmc">3177898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright CE, Strike PC, Brydon L, Steptoe A. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun. 2005;19:345–50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2004.10.003</ArticleId><ArticleId IdType="pubmed">15944074</ArticleId></ArticleIdList></Reference><Reference><Citation>Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry. 2013;70:812–20. https://doi.org/10.1001/jamapsychiatry.2013.1111</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2013.1111</ArticleId><ArticleId IdType="pubmed">23760347</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18:374–84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3691</ArticleId><ArticleId IdType="pubmed">28323260</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas CS, Amici M, Bortolotto ZA, Doherty A, Csaba Z, Fafouri A, et al. The role of JAK-STAT signaling within the CNS. Jakstat. 2013;2:e22925 https://doi.org/10.4161/jkst.22925</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/jkst.22925</ArticleId><ArticleId IdType="pubmed">24058789</ArticleId><ArticleId IdType="pmc">3670265</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Benedetto P, Ruscitti P, Berardicurti O, Panzera N, Grazia N, Di Vito Nolfi M, et al. Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. Arthritis Res Ther. 2021;23:213 https://doi.org/10.1186/s13075-021-02587-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02587-8</ArticleId><ArticleId IdType="pubmed">34391476</ArticleId><ArticleId IdType="pmc">8364029</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M, Rachayon M, Jirakran K, Sodsai P, Klinchanhom S, Gałecki P, et al. The immune profile of major dysmood disorder: proof of concept and mechanism using the precision nomothetic psychiatry approach. Cells. 2022; 11; https://doi.org/10.3390/cells11071183 .</Citation></Reference><Reference><Citation>Tian RH, Bai Y, Li JY, Guo KM. Reducing PRLR expression and JAK2 activity results in an increase in BDNF expression and inhibits the apoptosis of CA3 hippocampal neurons in a chronic mild stress model of depression. Brain Res. 2019;1725:146472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.146472</ArticleId><ArticleId IdType="pubmed">31545956</ArticleId></ArticleIdList></Reference><Reference><Citation>Shariq AS, Brietzke E, Rosenblat JD, Pan Z, Rong C, Ragguett RM, et al. Therapeutic potential of JAK/STAT pathway modulation in mood disorders. Rev Neurosci. 2018;30:1–7. https://doi.org/10.1515/revneuro-2018-0027</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2018-0027</ArticleId><ArticleId IdType="pubmed">29902157</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuyama T, Tschernig T, Qi Y, Volmer DA, Bäumer W. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions. Eur J Pharmacol. 2015;764:278–82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2015.06.060</ArticleId><ArticleId IdType="pubmed">26164790</ArticleId></ArticleIdList></Reference><Reference><Citation>Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80:865–75. https://doi.org/10.1136/annrheumdis-2020-219012</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-219012</ArticleId><ArticleId IdType="pubmed">33741556</ArticleId></ArticleIdList></Reference><Reference><Citation>Citera G, Jain R, Irazoque F, Madariaga H, Gruben D, Wang L, et al. Tofacitinib efficacy in patients with rheumatoid arthritis and probable depression/anxiety: post hoc analysis of phase 3 and 3b/4 randomized controlled trials. Rheumatol Ther. 2024;11:35–50. https://doi.org/10.1007/s40744-023-00612-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-023-00612-7</ArticleId><ArticleId IdType="pubmed">37925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao P, Chen C, Liu A, Shan Q, Zhu X, Jia C, et al. Early-life inflammation promotes depressive symptoms in adolescence via microglial engulfment of dendritic spines. Neuron. 2021;109:2573–2589.e2579. https://doi.org/10.1016/j.neuron.2021.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.06.012</ArticleId><ArticleId IdType="pubmed">34233151</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang R, Wang M, Li X, Wang H, Liu L, Wu Q, et al. Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway. J Neuroinflammation. 2022;19:41 https://doi.org/10.1186/s12974-022-02400-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02400-6</ArticleId><ArticleId IdType="pubmed">35130906</ArticleId><ArticleId IdType="pmc">8822843</ArticleId></ArticleIdList></Reference><Reference><Citation>Dranovsky A, Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry. 2006;59:1136–43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2006.03.082</ArticleId><ArticleId IdType="pubmed">16797263</ArticleId><ArticleId IdType="pmc">7537828</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinoto A, Ferrari S, Mariotto S. Treatment options in refractory autoimmune encephalitis. CNS Drugs. 2022;36:919–31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-022-00943-z</ArticleId><ArticleId IdType="pubmed">35917105</ArticleId><ArticleId IdType="pmc">9477937</ArticleId></ArticleIdList></Reference><Reference><Citation>Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 1996;711:163–74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(95)01415-2</ArticleId><ArticleId IdType="pubmed">8680860</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibenhener ML, Wooten MC. Use of the open field maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp. 2015;96:e52434 https://doi.org/10.3791/52434</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/52434</ArticleId></ArticleIdList></Reference><Reference><Citation>De-Fraja C, Conti L, Magrassi L, Govoni S, Cattaneo E. Members of the JAK/STAT proteins are expressed and regulated during development in the mammalian forebrain. J Neurosci Res. 1998;54:320–30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19981101)54:3&lt;320::AID-JNR3&gt;3.0.CO;2-R</ArticleId><ArticleId IdType="pubmed">9819137</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang Y, Lee WJ, Lee HS, Chu K, Lee SK, Lee ST. Tofacitinib treatment for refractory autoimmune encephalitis. Epilepsia. 2021;62:e53–e59. https://doi.org/10.1111/epi.16848</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.16848</ArticleId><ArticleId IdType="pubmed">33656171</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vries LCS, Duarte JM, De Krijger M, Welting O, Van Hamersveld PHP, Van Leeuwen-Hilbers FWM, et al. A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function. Inflamm Bowel Dis. 2019;25:647–60. https://doi.org/10.1093/ibd/izy364</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izy364</ArticleId><ArticleId IdType="pubmed">30668755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghersi-Egea JF, Mönkkönen KS, Schmitt C, Honnorat J, Fèvre-Montange M, Strazielle N. Blood-brain interfaces and cerebral drug bioavailability. Rev Neurol (Paris). 2009;165:1029–38. https://doi.org/10.1016/j.neurol.2009.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2009.09.011</ArticleId><ArticleId IdType="pubmed">19913860</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Liberto G, Pantelyushin S, Kreutzfeldt M, Page N, Musardo S, Coras R, et al. Neurons under T cell attack coordinate phagocyte-mediated synaptic stripping. Cell. 2018; 175: https://doi.org/10.1016/j.cell.2018.07.049 .</Citation></Reference><Reference><Citation>Chabot S, Williams G, Yong VW. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b. J Clin Invest. 1997;100:604–12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI119571</ArticleId><ArticleId IdType="pubmed">9239408</ArticleId><ArticleId IdType="pmc">508228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon SH, Han JK, Choi M, Kwon YJ, Kim SJ, Yi EH, et al. Dysfunction of microglial STAT3 alleviates depressive behavior via neuron-microglia interactions. Neuropsychopharmacology. 2017;42:2072–86. https://doi.org/10.1038/npp.2017.93</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2017.93</ArticleId><ArticleId IdType="pubmed">28480882</ArticleId><ArticleId IdType="pmc">5561349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordes J, Miranda L, Reinhardt M, Narayan S, Hartmann J, Newman EL, et al. Automatically annotated motion tracking identifies a distinct social behavioral profile following chronic social defeat stress. Nat Commun. 2023;14:4319 https://doi.org/10.1038/s41467-023-40040-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40040-3</ArticleId><ArticleId IdType="pubmed">37463994</ArticleId><ArticleId IdType="pmc">10354203</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, He ZX, Wang LM, Yuan W, Li LF, Hou WJ, et al. Voluntary wheel running reverses deficits in social behavior induced by chronic social defeat stress in mice: involvement of the dopamine system. Front Neurosci. 2019;13:256 https://doi.org/10.3389/fnins.2019.00256</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00256</ArticleId><ArticleId IdType="pubmed">31019446</ArticleId><ArticleId IdType="pmc">6458241</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z, Gibson SA, Buckley JA, Qin H, Benveniste EN. Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases. Clin Immunol. 2018;189:4–13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.09.014</ArticleId><ArticleId IdType="pubmed">27713030</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao L, Yu W, Liu Z, Zhao D, Lin S, Szalóki D, et al. JE-133 suppresses LPS-induced neuroinflammation associated with the regulation of JAK/STAT and Nrf2 signaling pathways. ACS Chem Neurosci. 2024;15:258–67. https://doi.org/10.1021/acschemneuro.3c00454</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.3c00454</ArticleId><ArticleId IdType="pubmed">38181172</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionisie V, Filip GA, Manea MC, Manea M, Riga S. The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies. Inflammopharmacology. 2021;29:75–90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-020-00777-5</ArticleId><ArticleId IdType="pubmed">33164143</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassamal S. Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories. Front Psychiatry. 2023;14:1130989.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2023.1130989</ArticleId><ArticleId IdType="pubmed">37252156</ArticleId><ArticleId IdType="pmc">10213648</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009;14:511–22. https://doi.org/10.1038/sj.mp.4002148</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4002148</ArticleId><ArticleId IdType="pubmed">18195714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Yao H, Zhang X, Liu L, Liu S, Dong Y. Comparison of LPS and MS-induced depressive mouse model: behavior, inflammation and biochemical changes. BMC Psychiatry. 2022;22:590 https://doi.org/10.1186/s12888-022-04233-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-022-04233-2</ArticleId><ArticleId IdType="pubmed">36064335</ArticleId><ArticleId IdType="pmc">9443001</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonoguchi HA, Kouo TWS, Kortagere S, Hillman J, Boyle DL, Mandyam CD. Lipopolysaccharide exposure differentially alters plasma and brain inflammatory markers in adult male and female rats. Brain Sci. 2022; 12. https://doi.org/10.3390/brainsci12080972 .</Citation></Reference><Reference><Citation>Bode JG, Ehlting C, Häussinger D. The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal. 2012;24:1185–94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2012.01.018</ArticleId><ArticleId IdType="pubmed">22330073</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardin F. NF-κB pathway and Hodgkin lymphoma. Biomedicines. 2022;10:2153.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10092153</ArticleId><ArticleId IdType="pubmed">36140254</ArticleId><ArticleId IdType="pmc">9495867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhor V, Le Charpentier T, Lebon S, Oré MV, Celador IL, Josserand J, et al. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun. 2013;32:70–85. https://doi.org/10.1016/j.bbi.2013.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2013.02.005</ArticleId><ArticleId IdType="pubmed">23454862</ArticleId><ArticleId IdType="pmc">3694309</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan P, Sheng WS, Hu S, Prasad S, Lokensgard JR. Differential cytokine-induced responses of polarized microglia. Brain Sci. 2021;11:1482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11111482</ArticleId><ArticleId IdType="pubmed">34827481</ArticleId><ArticleId IdType="pmc">8615503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasselin J, Schedlowski M, Karshikoff B, Engler H, Lekander M, Konsman JP. Comparison of bacterial lipopolysaccharide-induced sickness behavior in rodents and humans: Relevance for symptoms of anxiety and depression. Neurosci Biobehav Rev. 2020;115:15–24. https://doi.org/10.1016/j.neubiorev.2020.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2020.05.001</ArticleId><ArticleId IdType="pubmed">32433924</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Ali T, Liu Z, Gao R, Li A, Yang C, et al. EPO prevents neuroinflammation and relieves depression via JAK/STAT signaling. Life Sci. 2023;333:122102 https://doi.org/10.1016/j.lfs.2023.122102</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2023.122102</ArticleId><ArticleId IdType="pubmed">37769806</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona AW, Norden DM, Skendelas JP, Huang Y, O'Connor JC, Lawson M, et al. Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX<sub>3</sub>CR1)-deficient mice. Brain Behav Immun. 2013;31:134–42. https://doi.org/10.1016/j.bbi.2012.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2012.08.008</ArticleId><ArticleId IdType="pubmed">22926082</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden SA, Covington HE 3rd, Berton O, Russo SJ. A standardized protocol for repeated social defeat stress in mice. Nat Protoc. 2011;6:1183–91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2011.361</ArticleId><ArticleId IdType="pubmed">21799487</ArticleId><ArticleId IdType="pmc">3220278</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod KJ, English S, Ruuskanen SK, Taborsky B. Stress in the social context: a behavioural and eco-evolutionary perspective. J Exp Biol. 2023;226:jeb245829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jeb.245829</ArticleId><ArticleId IdType="pubmed">37529973</ArticleId><ArticleId IdType="pmc">10445731</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandl HB, Pruessner JC, Farine DR. The social transmission of stress in animal collectives. Proc Biol Sci. 2022;289:20212158.</Citation><ArticleIdList><ArticleId IdType="pubmed">35538776</ArticleId><ArticleId IdType="pmc">9091854</ArticleId></ArticleIdList></Reference><Reference><Citation>Masis-Calvo M, Schmidtner AK, de Moura Oliveira VE, Grossmann CP, de Jong TR, Neumann ID. Animal models of social stress: the dark side of social interactions. Stress. 2018;21:417–32. https://doi.org/10.1080/10253890.2018.1462327</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10253890.2018.1462327</ArticleId><ArticleId IdType="pubmed">29745275</ArticleId></ArticleIdList></Reference><Reference><Citation>Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62:812–8. https://doi.org/10.1016/j.jaad.2009.07.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2009.07.022</ArticleId><ArticleId IdType="pubmed">20219265</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyengar RL, Gandhi S, Aneja A, Thorpe K, Razzouk L, Greenberg J, et al. NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med. 2013;126:1017.e1011-7.e1018 https://doi.org/10.1016/j.amjmed.2013.02.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2013.02.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesripour A, Shahnooshi S, Hajhashemi V. Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice. J Complement Integr Med. 2019;17:20190016 https://doi.org/10.1515/jcim-2019-0016</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jcim-2019-0016</ArticleId></ArticleIdList></Reference><Reference><Citation>Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381–91. https://doi.org/10.1001/jamapsychiatry.2014.1611</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2014.1611</ArticleId><ArticleId IdType="pubmed">25322082</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler O, Krogh J, Mors O, Benros ME. Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol. 2016;14:732–42.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X14666151208113700</ArticleId><ArticleId IdType="pubmed">27640518</ArticleId><ArticleId IdType="pmc">5050394</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarapultsev A, Gusev E, Komelkova M, Utepova I, Luo S, Hu D. JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions. Mol Biomed. 2023;4:40 https://doi.org/10.1186/s43556-023-00151-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43556-023-00151-1</ArticleId><ArticleId IdType="pubmed">37938494</ArticleId><ArticleId IdType="pmc">10632324</ArticleId></ArticleIdList></Reference><Reference><Citation>Gałecka M, Szemraj J, Su KP, Halaris A, Maes M, Skiba A, et al. Is the JAK-STAT signaling pathway involved in the pathogenesis of depression? J Clin Med. 2022; 11: https://doi.org/10.3390/jcm11072056 .</Citation></Reference><Reference><Citation>Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133–45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00726-8</ArticleId><ArticleId IdType="pubmed">34987201</ArticleId><ArticleId IdType="pmc">8730299</ArticleId></ArticleIdList></Reference><Reference><Citation>Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4001805</ArticleId><ArticleId IdType="pubmed">16491133</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)67763-X</ArticleId><ArticleId IdType="pubmed">16399150</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42:151–7. https://doi.org/10.1016/j.jpsychires.2006.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2006.10.013</ArticleId><ArticleId IdType="pubmed">17174336</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat. 2009;5:433–49.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S5700</ArticleId><ArticleId IdType="pubmed">19721723</ArticleId><ArticleId IdType="pmc">2732010</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber MD, McKim DB, Niraula A, Witcher KG, Yin W, Sobol CG, et al. The influence of microglial elimination and repopulation on stress sensitization induced by repeated social defeat. Biol Psychiatry. 2019;85:667–8. https://doi.org/10.1016/j.biopsych.2018.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2018.10.009</ArticleId><ArticleId IdType="pubmed">30527629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Nang C, Luo F, Pan H, Zhang K, Liu J, et al. Esculetin attenuates lipopolysaccharide (LPS)-induced neuroinflammatory processes and depressive-like behavior in mice. Physiol Behav. 2016;163:184–92. https://doi.org/10.1016/j.physbeh.2016.04.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physbeh.2016.04.051</ArticleId><ArticleId IdType="pubmed">27133730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge L, Liu L, Liu H, Liu S, Xue H, Wang X, et al. Resveratrol abrogates lipopolysaccharide-induced depressive-like behavior, neuroinflammatory response, and CREB/BDNF signaling in mice. Eur J Pharmacol. 2015;768:49–57. https://doi.org/10.1016/j.ejphar.2015.10.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2015.10.026</ArticleId><ArticleId IdType="pubmed">26485503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>